Trade Aytu BioScience, Inc. - AYTU CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.122 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.444 |
| Open | 2.504 |
| 1-Year Change | 59.9% |
| Day's Range | 2.394 - 2.524 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | 2.444 | -0.060 | -2.40% | 2.504 | 2.544 | 2.314 |
| Sep 13, 2024 | 2.544 | 0.140 | 5.82% | 2.404 | 2.544 | 2.394 |
| Sep 12, 2024 | 2.414 | -0.070 | -2.82% | 2.484 | 2.514 | 2.314 |
| Sep 11, 2024 | 2.454 | 0.040 | 1.66% | 2.414 | 2.474 | 2.414 |
| Sep 10, 2024 | 2.422 | 0.020 | 0.83% | 2.402 | 2.422 | 2.392 |
| Sep 9, 2024 | 2.332 | -0.030 | -1.27% | 2.362 | 2.422 | 2.332 |
| Sep 6, 2024 | 2.362 | -0.020 | -0.84% | 2.382 | 2.382 | 2.292 |
| Sep 5, 2024 | 2.382 | 0.000 | 0.00% | 2.382 | 2.402 | 2.292 |
| Sep 4, 2024 | 2.382 | 0.060 | 2.58% | 2.322 | 2.402 | 2.252 |
| Sep 3, 2024 | 2.412 | 0.090 | 3.88% | 2.322 | 2.452 | 2.322 |
| Aug 30, 2024 | 2.352 | 0.010 | 0.43% | 2.342 | 2.452 | 2.252 |
| Aug 29, 2024 | 2.302 | -0.060 | -2.54% | 2.362 | 2.382 | 2.292 |
| Aug 28, 2024 | 2.262 | -0.060 | -2.58% | 2.322 | 2.402 | 2.232 |
| Aug 27, 2024 | 2.322 | -0.010 | -0.43% | 2.332 | 2.372 | 2.312 |
| Aug 26, 2024 | 2.342 | -0.010 | -0.43% | 2.352 | 2.462 | 2.292 |
| Aug 23, 2024 | 2.412 | -0.030 | -1.23% | 2.442 | 2.452 | 2.262 |
| Aug 22, 2024 | 2.442 | -0.190 | -7.22% | 2.632 | 2.662 | 2.392 |
| Aug 21, 2024 | 2.662 | -0.030 | -1.11% | 2.692 | 2.742 | 2.642 |
| Aug 20, 2024 | 2.712 | 0.130 | 5.03% | 2.582 | 2.752 | 2.572 |
| Aug 19, 2024 | 2.602 | 0.000 | 0.00% | 2.602 | 2.662 | 2.542 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aytu BioScience, Inc. Company profile
About Aytu Biopharma Inc
Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
Financial summary
BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.
Equity composition
Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.
| Industry: | Pharmaceuticals (NEC) |
7900 E. Union Avenue
Suite 920
DENVER
COLORADO 80237
US
News
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com